UNITED STATES SECURITIES AND EXCHANGE COMMISSION (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39083 Vir Biotechnology, Inc. (Exact Name of Registrant as Specified in Its Charter) WASHINGTON, DC 20549 FORM 10-Q Delaware 81-2730369 (State or Other Jurisdic ...

NIR WHO: World Health Organization; HBV: Hepatitis B Virus; HIV: Human Immunodeficiency Virus A World Without Infectious Disease Corporate Overview February 24, 2022 VIR BIOTECHNOLOGY, INC. LEGAL DISCLAIMER Forward-Looking Statements Statements in this presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding the nearterm financial performance (including near-term collaboration revenue related to ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR Securities registered pursuant to Section 12(b) of the Act: ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 1-39083 Vir Biotechnology, Inc. (Exact Name of Registrant as Specified in its ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39083 Vir Biotechnology, Inc. (Exact name of registrant as specified in its charter) | Delaware | 81-2730369 | | --- | --- | ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39083 Vir Biotechnology, Inc. (Exact name of registrant as specified in its charter) | Delaware | 81-2730369 | | --- | --- | | (St ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Vir Biotechnology, Inc. (Exact name of registrant as specified in its charter) WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39083 Indicate by check mark whether the registran ...

1 | --- | --- | --- | --- | --- | --- | |-----------------------------------------------------------------------------------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | A WORLD WITHOUT INFECTIOUS DISEASE | | | | | | | Vir Biotechnology, Inc. 20th Annual Needham Healthcare Conference April 13, 2021 | | | | | | Legal disclaimers Forward-Looking Statements Statements in this presentation that are not statements of historical fact are forward-looking statements. Such for ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 1-39083 Vir Biotechnology, Inc. (Exact name of Registrant as specified in its Charter) Delaware 81-2730369 (State or other jurisdiction o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39083 Vir Biotechnology, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 81-2730369 (State or other juri ...

| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------|-------------------|-------|------------------------------------|---------------------|-------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | A WORLD WITHOUT INFECTIOUS DISEASE | | | | | | | | | | Vir August 2020 | | | Biotechnology, Inc. | | | | | | | Legal disclaimers Forward-Looking Statements Statements in this presentation that are not statements of historical fact are forward- ...